In a major shift, cancer drugs go 'tissue-agnostic'.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Mitochondrial transporter expression patterns distinguish tumor from normal tissue and identify cancer subtypes with different survival and metabolism.Scientific reports · 2022
   Article
2. Assessing the utility and attitudes toward molecular testing in neuro-oncology: a survey of the Society for Neuro-Oncology members.Neuro-oncology practice · 2021
   Article
3. Lynch syndrome for the gynaecologist.The obstetrician & gynaecologist : the journal for continuing professional development from the Royal College of Obstetricians & Gynaecologists · 2021
   Review
4. The Community Oncology and Academic Medical Center Alliance in the Age of Precision Medicine: Cancer Genetics and Genomics Considerations.Journal of clinical medicine · 2020
   Review
5. Oncologist Confidence in Genomic Testing and Implications for Using Multimarker Tumor Panel Tests in Practice.JCO precision oncology · 2020
   Article
6. Whole-exome sequencing of 79 xenografts as a potential approach for the identification of genetic variants associated with sensitivity to cytotoxic anticancer drugs.PloS one · 2020
   Article
7. Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States.JCO precision oncology · 2018
   Article
8. TumorFusions: an integrative resource for cancer-associated transcript fusions.Nucleic acids research · 2018
   Article
9. The future of DNA sequencing.Nature · 2017
   Article
10. Resources for Interpreting Variants in Precision Genomic Oncology Applications.Frontiers in oncology · 2017
    Review
11. Trial watch: Immune checkpoint blockers for cancer therapy.Oncoimmunology
    Review

Corrections and comments

• Comment on
  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.2017

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as